** Shares of drug developer Halozyme Therapeutics HALO.O gain ~13% to $51.5 premarket
** Co withdraws offer to buy German drug developer Evotec EVTG.DE for 11 euro per share, or 2 billion euros ($2.09 billion)
** U.S.-listed shares of Evotec EVO.O down about 17% at $4.43 before the bell
** HALO CEO Helen Torley says EVO "has been unwilling to engage with us to explore a potential combination and a company spokesperson has publicly commented that its goal is to remain an independent company"
** Adds that multiple requests to meet with the chairwoman of EVO's supervisory board were not accepted
** HALO announced its proposal to buy EVO on Nov 14
** As of last close, HALO up ~24% YTD and EVO down ~53% YTD
($1 = 0.9589 euros)
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.